Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Connective Tissue Diseases AND Connective Tissue Disorders AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44353   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    554 result(s) found for: Connective Tissue Diseases AND Connective Tissue Disorders AND Placebo. Displaying page 21 of 28.
    «« First « Previous 17  18  19  20  21  22  23  24  25  Next» Last»»
    EudraCT Number: 2012-004342-14 Sponsor Protocol Number: VX12-509-104 Start Date*: 2013-04-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) EE (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003558-34 Sponsor Protocol Number: GS-US-445-4189 Start Date*: 2017-07-03
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome
    Medical condition: Active Sjogren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004673-16 Sponsor Protocol Number: MA29585 Start Date*: 2016-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arth...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000855-35 Sponsor Protocol Number: HZNP-DAX-204 Start Date*: 2022-09-23
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003417-95 Sponsor Protocol Number: 201247 Start Date*: 2017-01-13
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explo...
    Medical condition: Systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000993-31 Sponsor Protocol Number: CLOU064A2201 Start Date*: 2019-04-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebo- controlled phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patien...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) FR (Completed) SK (Completed) HU (Completed) BE (Completed) ES (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000471-37 Sponsor Protocol Number: CLOU064A2301 Start Date*: 2021-10-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urt...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) ES (Ongoing) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-000107-40 Sponsor Protocol Number: GRC4039-203 Start Date*: 2011-06-16
    Sponsor Name:Glenmark Pharmaceuticals SA
    Full Title: A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumato...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002534-16 Sponsor Protocol Number: FSJD-INNOVA-2020 Start Date*: 2021-10-15
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: 12-month randomized, double-blind, placebo-controlled, pharmacological clinical trial to evaluate the effectiveness, cost-utility and neurobiological effects of low-dose Naltrexone in patients with...
    Medical condition: Fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004633-96 Sponsor Protocol Number: D3461C00005 Start Date*: 2015-07-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) PL (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005771-39 Sponsor Protocol Number: RVLO221-02 Start Date*: 2023-03-16
    Sponsor Name:Revolo Biotherapeutics Ltd
    Full Title: A Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001447-27 Sponsor Protocol Number: ANB019-301 Start Date*: 2021-12-08
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis
    Medical condition: Subjects with generalized pustular psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016266-90 Sponsor Protocol Number: EFC11072 Start Date*: 2011-05-03
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: Estudio aleatorizado, doble-ciego, controlado con placebo, multicéntrico, de dos partes, de búsqueda de dosis y confirmatorio, con un diseño operacionalmente adaptativo que evalúa la eficacia y seg...
    Medical condition: Artritis Reumatoide _____________________________________ Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FI (Completed) HU (Completed) EE (Completed) DE (Completed) LT (Completed) PT (Completed) NL (Completed) GR (Completed) RO (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003622-13 Sponsor Protocol Number: 1311.28 Start Date*: 2016-03-07
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: BI 655066 versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltIMMa-2)
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) PT (Completed) ES (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002609-93 Sponsor Protocol Number: DRI17224 Start Date*: 2021-09-03
    Sponsor Name:Sanofi aventis recherche et developpement
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic sponta...
    Medical condition: Chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed) PL (Completed) GR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017938-46 Sponsor Protocol Number: M11-328 Start Date*: 2010-08-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis
    Medical condition: Enthesitis Related Arthritis (ERA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10003246 Arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) IE (Completed) SE (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004632-19 Sponsor Protocol Number: D3461C00004 Start Date*: 2015-08-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) ES (Completed) CZ (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-005760-57 Sponsor Protocol Number: CA42750 Start Date*: 2021-08-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023482-21 Sponsor Protocol Number: 01/10/CPT/TP3 Start Date*: 2011-04-11
    Sponsor Name:PLIVA HRVATSKA d.o.o.
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group Study of the Efficacy and Safety of a PLIVA Ointment (Calcipotriol + Betamethasone 50 µg/g + 0.5 mg/g ointment) versus Vehicle and Dovobet® i...
    Medical condition: mild to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003191-30 Sponsor Protocol Number: CLYS006X2201 Start Date*: 2018-07-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject and investigator blinded, placebo-controlled, multi-center study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammator...
    Medical condition: Inflammatory Acne
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 17  18  19  20  21  22  23  24  25  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Aug 11 05:45:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA